Deutsche Bank reiterated its Buy rating on Alexion Pharmaceuticals ALXN. At the moment, DB has a price target of $53 placed on the company's stock. On Monday, ALXN added 0.14% to its value to end the day at $50.37.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
